Inhibitor Therapeutics (INTI) Non-Current Debt (2020 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Non-Current Debt came in at $29380.0 in Q1 2026, down 49.66% YoY from $58361.0 in Q1 2025, and down 20.36% on a QoQ basis from $36889.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Non-Current Debt (2020 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 4 years of Non-Current Debt data on file, last reported at $29380.0 in Q1 2026.
- Quarterly Non-Current Debt fell 49.66% year-over-year to $29380.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29380.0 (down 49.66% YoY) and the FY2025 annual result came in at $36889.0, changed N/A from the prior year.
- Non-Current Debt declined to $29380.0 in Q1 2026, from $36889.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $58361.0 in Q1 2025 to a low of $29380.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 21,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,380.00 |
| Dec 31, 2025 | 36,889.00 |
| Sep 30, 2025 | 44,181.00 |
| Jun 30, 2025 | 52,064.00 |
| Mar 31, 2025 | 58,361.00 |
| Mar 31, 2021 | 104,000.00 |
| Dec 31, 2020 | 55,000.00 |
| Sep 30, 2020 | 18,489.00 |
| Jun 30, 2020 | 25,422.00 |